The presentations include the one given by Dr. María Pérez Torres, who received the award for the best oral communication for a project on the use of mesenchymal cells to reduce complications after hematopoietic progenitor transplantation.

Thanks to the donation, the Childhood Cancer and Blood Disorders group at VHIR is doing research to explore the use of liquid biopsy for the prediction of the evolution of patients with this rare disease.

Dr. Lucas Moreno is the first author of the international work that presents a series of considerations for early phase studies with the aim of accelerating the arrival of new therapies to patients with childhood cancer.

El 20% dels pacients en els quals s’havia trobat alguna predisposició genètica van ser diagnosticats amb algun tipus de tumor i van poder iniciar el tractament de manera precoç.

The funded project is investigating the biological mechanisms of metastasis and hopes to improve the survival of patients with this type of tumor with the development of new therapies.

SIOPEN promotes research and the implementation of clinical trials to improve clinical practice in this type of childhood tumor.

RADeep aims to map at the European level the diagnostic methods, demography, survival rate, main clinical features and treatments of rare anaemia disorders patients.

Vall d’Hebron ha celebrat avui la Jornada del Dia Mundial contra el Càncer, una malaltia cada cop més freqüent que patiran al llarg de la vida un de cada dos homes i una de cada tres dones del nostre entorn.

The selected studies were those of Dr. Carlos Jiménez, from the Cancer and Childhood Hematological Diseases group, and Dr. Eva Coll, from the Biomedical Research in Gynecology group, both members of eCORE-Cancer.

Amb motiu del Dia Mundial del Càncer, la fotògrafa Ximena Borrazas i Vall d’Hebron col·laboren en un projecte fotogràfic per recaptar fons per investigar en la lluita contra la malaltia.

The funds come from the campaign "Una pizca de Magia" (A pinch of Magic) promoted by Tamara Gorro.

The awarded initiatives are research for a non-invasive diagnosis of endometrium cancer and a project to improve the efficiency of RNA therapies.

The donation will allow to continue promoting research projects to understand and find new therapies for pediatric nervous system tumors and childhood sarcomas.

The inhibition of integrin alpha9 (ITGA9) by the drug RA08 is a novel therapeutic strategy to prevent the dissemination of tumor cells.

The association and VHIR have signed a collaboration agreement to fund with 150,000€ a project to find new therapeutic strategies for this childhood tumor of the central nervous system.

The presentations address the discovery of new drugs and therapeutic targets, clinical trial results and the improvement of clinical practice and patient experience.

The technique developed at Vall d'Hebron Research Institute (VHIR) uses a "switch" to block the reproduction of neuroblastoma cells

This is the first international study on the incidence of Mediterranean nutrition on the side effects of cancer treatments and survival of pediatric cancer patients.

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

The study, coordinated by Vall d'Hebron, aims to facilitate access to personalized medicine for all children and adolescents with cancer, regardless of where they live.

Dr. Luz Uria was recognized for the best communication of the Congress of the Sociedad Española de Hematología y Oncología Pediátrica, the second place was for Dr. Raquel Hladun.

The meeting allows establishing the basis for collaboration between experts from around the world, with the aim of promoting research on this protein and its role in cancer.

In pediatric cancers, sarcomas account for 14% of cases and 20% of deaths.

These studies, part of the BEACON project, describe the efficacy of a new immunotherapy treatment for neuroblastoma and the usefulness of new biomarkers in predicting the prognosis and response to therapy.